A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. This phase III study (NCT01034462) evaluated the efficacy, the safety, and the tolerability of 40 to 120 mg/d of levomilnacipran ER versus placebo in the treatment of patients (18-80 y) with major depressive disorder. This multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study comprised a 1-week single-blind, placebo run-in period; an 8-week double-blind treatment; and a 2-week double-blind down-taper period. The primary efficacy parameter was total score change from baseline to week 8 on the Montgomery-Åsberg Depression Rating Scale (MADRS); the secondary efficacy was the Sheehan Disability Scale. Analysis was performed using the mixed-effects model for repeated measures on a modified intent-to-treat population. A total of 434 patients received at least 1 dose of double-blind treatment (safety population); 429 patients also had 1 or more postbaseline MADRS assessments (modified intent-to-treat population). The least squares mean differences and 95% confidence interval were statistically significant in favor of levomilnacipran ER versus placebo for the MADRS total score (-3.095 [-5.256, -0.935]; P = 0.0051) and the SDS total score (-2.632 [-4.193, -1.070]; P = 0.0010) change from baseline to week 8. Adverse events were reported in 61.8% of the placebo patients and in 81.6% of the levomilnacipran ER patients. Frequently reported adverse events (≥ 5% in levomilnacipran ER and twice the rate of placebo) were nausea, dizziness, constipation, tachycardia, urinary hesitation, hyperhidrosis, insomnia, vomiting, hypertension, and ejaculation disorder. In conclusion, there was a statistically significant difference in the score change from baseline to week 8 between levomilnacipran ER and placebo on several depression rating scales, reflecting symptomatic and functional improvement; treatment was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Self-citationThe Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
McKnight, P. E., & Kashdan, T. B. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.005 · Cited by 400 · cited 2×
“Research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind changes in symptoms.(4,5) As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better i…”
BackgroundKeller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 6×
“This phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group, flexible-dose study compared 40 to 120 mg/d of levomilnacipran ER with placebo in adult outpatients with MDD.”
BackgroundInfluentialHirschfeld, R. M. A., Dunner, D. L., Keitner, G., Klein, D. N., Koran, L. M., Kornstein, S. G., Markowitz, J. C., Miller, I., Nemeroff, C. B., Ninan, P. T., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01291-4 · Cited by 231 · cited 1×
“Research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind changes in symptoms.(4,5) As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better i…”
BackgroundSheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328341bb5f · Cited by 124
Self-citationMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Cited by
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182
Self-citationBakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130040 · Cited by 70
Self-citationCardiovascular adverse effects of newer antidepressants
Mago, R., Tripathi, N., & Andrade, C. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908709 · Cited by 54
“While one study [79] noted that no patient in the levomilnacipran group met PCS criteria for change in heart rate, the other short-term studies did not report the proportion of patients meeting criteria for a clinically meaningful increase in heart rate.”
ResultLee, S. M., Dong, T. S., Krause-Sorio, B., Siddarth, P., Milillo, M. M., Lagishetty, V., Datta, T., Aguilar-Faustino, Y., Jacobs, J. P., & Lavretsky, H. (2022) · International Psychogeriatrics · doi:10.1017/s1041610221000120 · Cited by 43
Metadata
- Authors
- Sambunaris, A., Bose, A., Gommoll, C. P., Chen, C., Greenberg, W. M., & Sheehan, D. V.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2014-02
- Volume
- 34
- Issue
- 1
- Pages
- 47-56
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1995472991
- Cited by
- 90
- References
- 15
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0000000000000060
- The paper
- Sambunaris, A., Bose, A., Gommoll, C. P., Chen, C., Greenberg, W. M., & Sheehan, D. V. (2014). A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.